Disease burden, symptoms, and use of analgesics in patients with psoriasis with or without psoriatic arthritis: A cross-sectional study
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Disease burden, symptoms, and use of analgesics in patients with psoriasis with or without psoriatic arthritis : A cross-sectional study. / Loft, Nikolai; Nguyen, Thao Thi; Kristensen, Lars Erik; Thyssen, Jacob P.; Egeberg, Alexander.
In: Journal of the American Academy of Dermatology, Vol. 86, No. 3, 03.2022, p. 590-597.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Disease burden, symptoms, and use of analgesics in patients with psoriasis with or without psoriatic arthritis
T2 - A cross-sectional study
AU - Loft, Nikolai
AU - Nguyen, Thao Thi
AU - Kristensen, Lars Erik
AU - Thyssen, Jacob P.
AU - Egeberg, Alexander
N1 - Funding Information: Dr Loft has been an honorary speaker for Eli Lilly and Janssen Cilag. Dr. Nguyen reports no potential conflicts of interest. Dr Kristensen has received fees for as a speaker and consultant for Pfizer, AbbVie, Amgen, Forward pharma, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. Dr Thyssen reports no relevant conflicts of interest. Dr Egeberg has received research funding from Pfizer, Eli Lilly , Novartis, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation , the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation , and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Sun Pharmaceuticals, Galapagos NV, Samsung Bioepis Co, Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals. Funding Information: Dr Loft has been an honorary speaker for Eli Lilly and Janssen Cilag. Dr. Nguyen reports no potential conflicts of interest. Dr Kristensen has received fees for as a speaker and consultant for Pfizer, AbbVie, Amgen, Forward pharma, UCB, Gilead, Biogen, BMS, MSD, Novartis, Eli Lilly, and Janssen Pharmaceuticals. Dr Thyssen reports no relevant conflicts of interest. Dr Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Sun Pharmaceuticals, Galapagos NV, Samsung Bioepis Co, Ltd., Pfizer, Eli Lilly and Company, Novartis, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, and Janssen Pharmaceuticals. Funding sources: None. Publisher Copyright: © 2021 American Academy of Dermatology, Inc.
PY - 2022/3
Y1 - 2022/3
N2 - Background: Patients with psoriasis have an impaired quality of life and higher use of analgesics than the general population. Whether such use is due to skin pain or a consequence of joint pain resulting from psoriatic arthritis (PsA) is not clear. Objectives: To assess symptoms, disease burden, and use of analgesics in patients with psoriasis with and without PsA. Method: Symptoms, general health (EurQol 5-dimension and 5-levels), and use of analgesics were assessed in patients with psoriasis and the general population from the Danish Skin Cohort. Results: We included 4016 patients with psoriasis (847 with concomitant PsA) and 3490 reference individuals. For patients with psoriasis having PsA, itch, skin pain, and/or joint pain was associated with worse general health. Use of opioids within 12 months was observed among 9.0% of the general population, 14.2% of patients with psoriasis without PsA, and 22.7% of patients with concomitant PsA. Of the symptoms, only joint pain was associated with use of analgesics (odds ratio, 3.72 (2.69-5.14); P < .0001). Limitations: Cross-sectional design. Conclusion: Patients with psoriasis (especially concomitant PsA) have a higher use of analgesics compared with the general population, which appears to be a result of increased joint pain.
AB - Background: Patients with psoriasis have an impaired quality of life and higher use of analgesics than the general population. Whether such use is due to skin pain or a consequence of joint pain resulting from psoriatic arthritis (PsA) is not clear. Objectives: To assess symptoms, disease burden, and use of analgesics in patients with psoriasis with and without PsA. Method: Symptoms, general health (EurQol 5-dimension and 5-levels), and use of analgesics were assessed in patients with psoriasis and the general population from the Danish Skin Cohort. Results: We included 4016 patients with psoriasis (847 with concomitant PsA) and 3490 reference individuals. For patients with psoriasis having PsA, itch, skin pain, and/or joint pain was associated with worse general health. Use of opioids within 12 months was observed among 9.0% of the general population, 14.2% of patients with psoriasis without PsA, and 22.7% of patients with concomitant PsA. Of the symptoms, only joint pain was associated with use of analgesics (odds ratio, 3.72 (2.69-5.14); P < .0001). Limitations: Cross-sectional design. Conclusion: Patients with psoriasis (especially concomitant PsA) have a higher use of analgesics compared with the general population, which appears to be a result of increased joint pain.
KW - analgesics
KW - itch
KW - opioids
KW - pain
KW - patient-reported outcomes
KW - psoriasis
KW - psoriatic arthritis
KW - quality of life
U2 - 10.1016/j.jaad.2021.07.028
DO - 10.1016/j.jaad.2021.07.028
M3 - Journal article
C2 - 34314746
AN - SCOPUS:85112108018
VL - 86
SP - 590
EP - 597
JO - American Academy of Dermatology. Journal
JF - American Academy of Dermatology. Journal
SN - 0190-9622
IS - 3
ER -
ID: 314145620